Related Experiment Video
Updated: Oct 29, 2025
A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
Published on: May 22, 2019
Aberrant lung lipids cause respiratory impairment in a Mecp2-deficient mouse model of Rett syndrome
Neeti Vashi1,2, Cameron Ackerley3, Martin Post3
1Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A1, Canada.
Abstract:
Severe respiratory impairment is a prominent feature of Rett syndrome, an X-linked disorder caused by mutations in methyl CpG-binding protein 2 (MECP2). Despite MECP2's ubiquitous expression, respiratory anomalies are attributed to neuronal dysfunction. Here, we show that neutral lipids accumulate in mouse Mecp2-mutant lungs, whereas surfactant phospholipids decrease. Conditional deletion of Mecp2 from lipid-producing alveolar epithelial 2 (AE2) cells causes aberrant lung lipids and respiratory symptoms, whereas deletion of Mecp2 from hindbrain neurons results in distinct respiratory abnormalities. Single-cell RNA sequencing of AE2 cells suggests lipid production and storage increase at the expense of phospholipid synthesis. Lipid production enzymes are confirmed as direct targets of MECP2-directed nuclear receptor co-repressor 1/2 transcriptional repression. Remarkably, lipid-lowering fluvastatin improves respiratory anomalies in Mecp2-mutant mice. These data implicate autonomous pulmonary loss of MECP2 in respiratory symptoms for the first time and have immediate impacts on patient care.
Insights
Rett syndrome lung cells show abnormal lipid buildup due to MECP2 mutations, causing respiratory issues. Treating mice with fluvastatin improved breathing, suggesting a new therapeutic target for this neurological disorder.
Area of Science:
- Cell Biology
- Genetics
- Pulmonology
Background:
- Rett syndrome, an X-linked disorder, presents with severe respiratory impairment.
- Mutations in methyl CpG-binding protein 2 (MECP2) are the primary cause.
- Respiratory issues are often linked to neuronal dysfunction.
Purpose of the Study:
- To investigate the role of MECP2 in lung physiology beyond neuronal function.
- To identify the cellular mechanisms underlying respiratory impairment in MECP2-deficient models.
- To explore potential therapeutic interventions for respiratory symptoms in Rett syndrome.
Main Methods:
- Analysis of lung lipid profiles in Mecp2-mutant mice.
- Conditional deletion of Mecp2 in alveolar epithelial 2 (AE2) cells and hindbrain neurons.
- Single-cell RNA sequencing of AE2 cells.
- Investigation of transcriptional regulation by MECP2.
- Pharmacological treatment with fluvastatin.
Main Results:
- Accumulation of neutral lipids and decreased surfactant phospholipids in Mecp2-mutant lungs.
- Conditional deletion of Mecp2 in AE2 cells recapitulated lung lipid abnormalities and respiratory symptoms.
- Deletion of Mecp2 in hindbrain neurons caused distinct respiratory deficits.
- AE2 cell lipidomics revealed increased lipid production/storage at the expense of phospholipid synthesis.
- Lipid production enzymes are direct targets of MECP2-mediated transcriptional repression.
- Flurvastatin treatment ameliorated respiratory anomalies in Mecp2-mutant mice.
Conclusions:
- Loss of MECP2 in pulmonary alveolar epithelial cells autonomously contributes to respiratory symptoms in Rett syndrome.
- Aberrant lipid metabolism in lung cells is a key pathogenic mechanism.
- Targeting lipid metabolism with drugs like fluvastatin offers a promising therapeutic strategy for respiratory complications.
